[1] |
Brunt EM,Janney CG,Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999, 94(9): 2467-2474.
|
[2] |
范建高,魏国华.非酒精性脂肪性肝病的诊断.中华肝脏病杂志, 2005, 13(9): 710-711.
|
[3] |
Lee S,Charters AC,Chandler JG, et al. A technique for orthotopic liver transplantation in the rat. Transplantation, 1973, 16(6): 664-669.
|
[4] |
Kamada N,Calne RY. Orthotopic liver transplantation in the rat: technique using cuff for portal vein anastomosis and biliary drainage. Transplantation, 1979, 28(1): 47-50.
|
[5] |
Fishbein TM,Fiel MI,Emre S, et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation, 1997, 64(2): 248-251.
|
[6] |
Busuttil RW,Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl, 2003, 9(7): 651-663.
|
[7] |
Cameron A,Busuttil RW. AASLD/ILTS transplant course: is there an extended donor suitable for everyone?Liver Transpl, 2005, 11(11 Suppl 1): S2-S5.
|
[8] |
Zamboni F,Franchello A,David E, et al. Effect of macrovescicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin Transplant, 2001, 15(1): 53-57.
|
[9] |
Strasberg SM,Howard TK,Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology, 1994, 20(4 Pt 1): 829-838.
|
[10] |
Loinaz C,González EM. Marginal donors in liver transplantation. Hepatogastroenterology, 2000, 47(31): 256-263.
|
[11] |
Salizzoni M,Franchello A,Zamboni F, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int, 2003, 16(7): 486-493.
|
[12] |
Nakano H,Nagasaki H,Barama A, et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet. Hepatology, 1997, 26(3): 670-678.
|
[13] |
Serafín A,Roselló-Catafau J,Prats N, et al. Ischemic preconditioning increases the tolerance of fatty liver to hepatic ischemia-reperfusion injury in the rat. Am J Pathol, 2002, 161(2): 587-601.
|
[14] |
Nanji AA. Another animal model for nonalcoholic steatohepatitis: how close to the human condition. Am J Clin Nutr, 2004, 79(3): 350-351.
|
[15] |
Jiang H,Qu L,Li Y, et al. Bone marrow mesenchymal stem cells reduce intestinal ischemia/reperfusion injuries in rats. J Surg Res, 2011, 168(1): 127-134.
|
[16] |
Chui AK,Shi LW,Rao AR, et al. Donor fatty (steatotic) liver allografts in orthotopic liver transplantation: a revisit. Transplant Proc, 2000, 32(7): 2101-2102.
|
[17] |
Ureña MA,Ruiz-Delgado FC,González EM, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc, 1998, 30(7): 3288-3291.
|
[18] |
Li Y,Zhang D,Zhang Y, et al. Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation. J Biomed Sci, 2010, 17: 75.
|
[19] |
Cao H,Qian H,Xu W, et al. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett, 2010, 32(5): 725-732.
|
[20] |
Xu J,Deng X,Demetriou AA, et al. Factors released from cholestatic rat livers possibly involved in inducing bone marrow hepatic stem cell priming. Stem Cells Dev, 2008, 17(1): 143-155.
|